A case report of paroxysmal extreme pain disorder caused by SCN9A gene mutation
10.3760/cma.j.cn101070-20200108-00032
- VernacularTitle:SCN9A基因突变引起阵发性剧痛症1例
- Author:
Hua LI
;
Mei OUYANG
;
Yang JIN
;
Peiqi ZHANG
;
Jing GUO
;
Hongjun YAN
;
Liming ZHAO
- From:
Chinese Journal of Applied Clinical Pediatrics
2021;36(9):702-705
- CountryChina
- Language:Chinese
-
Abstract:
The clinical data of a case of paroxysmal extreme pain disorder(PEPD) in Guangdong 999 Brain Hospital were retrospectively analyzed.The male patient, age of first examination was 7 months, began to have recurrent tonic accompanied by facial redness or cyanosis at 5 months after birth.The patient was diagnosed with epilepsy.The oral solution of sodium valproate and Levetiracetam were not effective.The video electroencephalogram examination displayed that, when the patient had tonic and bradycardia, the synchro electroencephalogram did not show epileptic discharge, so the patient was considered to have non-epileptic tonic.Genetic examination suggested that SCN9A gene mutation of c. 5240T >C resulted in amino acid changes: Val1747Ala.Combined with the skin changes, the patient was diagnosed as PEPD caused by SCN9A gene mutation.After the treatment with Carbamazepine, the patient′s abnormal skin changed and his-epileptic tonic disappeared, and his condition improved significantly.The early stage of PEPD can be mainly manifested as non-epileptic tonic.It is easy to be misdiagnosed as epilepsy, so the patient′s characteristic skin changes should be noticed, and genetic examination is also helpful in the diagnosis of the disease.
